Company Profile About Archimedes PharmaArchimedes Pharma is an international specialty pharmaceutical company with an established commercial organization in the UK, US, France, Germany, Ireland, and Spain and a portfolio of products marketed to specialist prescribers. Archimedes Pharma's products include: - Gliadel, high grade glioma;
- Zomorph, an oral sustained release morphine product for cancer pain;
- Oramorph, an immediate release liquid morphine product for moderate to severe pain;
- Apomorphine Injection for motor fluctuations in advanced Parkinson's disease;
- Pabrinex, a high potency formulation of vitamins B and C for alcohol misuse.
Archimedes Pharma's strategy is to grow its commercial presence organically, through the acquisition of marketed brands and through partnering or licensing of European or US rights to new specialist prescribed products. In parallel, Archimedes Pharma is also developing a robust pipeline of innovative near term products to support its commercial organization. Archimedes Pharma's lead product is PecFent®, an innovative fentanyl nasal spray developed for breakthrough cancer pain utilising the Company's proprietary PecSysTM delivery technology. The CHMP has recommended PecFent® be authorized for marketing in European Union countries for the treatment of breakthrough cancer pain and Archimedes Pharma anticipates launch in 2010. Archimedes Pharma has also filed for regulatory approval in the US. To provide further impetus and sales growth for the company in the medium term, Archimedes Pharma has an established development organization with proprietary technologies for nasal and oral drug delivery and a number of products in development. These capabilities and technologies are also offered to pharmaceutical companies on a fee-for-service or licensing basis.
| 
